FDA issues expanded indication clearance for Medtronic Pillcam Colon 2 capsule

Medtronic has announced receipt of FDA clearance for expanded indication of use regarding its PillCam Colon 2 capsule endoscope.

The vitamin-sized camera—the only non-invasive diagnostic test capable of directly visualizing polyps in the colons of patients at major risks for colonoscopy or moderate sedation—now has expanded indication for the detection of colon polyps in patients with evidence of lower gastrointestinal bleeding.

"We are committed to the early detection and treatment of chronic GI diseases and cancers,” said Medtronic’s Vafa Jamali in a company press release. “We are pleased with the FDA's decision to clear this expanded indication for PillCam Colon capsule which will provide access to more patients who can benefit from this technology.”

The device, which does not require sedation, anesthesia or radiation, may also limit the risk of complications associated with colonoscopy such as perforation, bleeding or cardio-pulmonary complications.

Read the full Medtronic press release here.

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.